Psychiatric Times

02/20/2026

The FDA has accepted Teva Pharmaceuticals' NDA for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of adults with schizophrenia.

The FDA accepts Teva’s once-monthly olanzapine injection for schizophrenia, promising steadier adherence without mandatory 3-hour monitoring.

02/20/2026

Psychedelic therapies surge in trials, but safety varies by substance—learn key benefits, risks, and why psychiatric history raises complications in our latest Special Report article:

Psychedelic therapies surge in trials, but safety varies by substance—learn key benefits, risks, and why psychiatric history raises complications.

02/18/2026

Mitigating the psychosocial, social, and physical harms of climate change requires not only addressing global temperature changes but confronting the longstanding social inequities that magnify its effects.

Read more in our latest Tales From the Clinic article: https://www.psychiatrictimes.com/view/forced-uprooting-effects-of-climate-on-mood-and-behavior

02/17/2026

Compass Pathways today announced the successful achievement of the primary endpoint in the ongoing phase 3 COMP006 trial evaluating 2 fixed doses of COMP360—a synthetic, proprietary formulation of psilocybin for managing treatment-resistant depression.

Phase 3 trial shows COMP360 psilocybin rapidly reduces treatment-resistant depression symptoms with durable effects and good safety, as Compass moves toward FDA review.

02/16/2026

Reality TV shows therapy and mental health diagnoses as entertainment—raising stigma, misinformation, and su***de concerns. Here's what psychiatrists and mental health clinicians need to know: https://www.psychiatrictimes.com/view/keeping-up-with-the-ketamine-psychiatric-diagnoses-and-treatment-on-reality-tv

02/13/2026

These researchers are currently evaluating the hypothesis that reducing stress and depression during pregnancy can also minimize cardiovascular health for the mother and her child. Learn more here:

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.

02/11/2026

Our February cover stories explore both sides of the discussion on antidepressant withdrawal.

According to Nicolas Badre, David Cohen, and Camila Strassle, antidepressant withdrawal is more common and severe than previously acknowledged: https://www.psychiatrictimes.com/view/exiting-antidepressants-a-needed-spotlight-on-withdrawal

According to Ronald Pies and Jonathan F. Henssler, antidepressant discontinuation can be averted by slow, careful, individualized tapering, and by avoiding short half-life agents: https://www.psychiatrictimes.com/view/antidepressant-withdrawal-syndromes-listening-to-the-patient-and-taking-it-slow

Read both stories in our interactive digital issue: https://indd.adobe.com/view/5e75daed-86f0-43ab-8dc3-eaa07d53856b

02/10/2026

💤 The FDA has accepted a New Drug Application and granted Priority Review for Takeda's oveporexton for the treatment of narcolepsy type 1.

FDA grants priority review to Takeda’s orexin agonist oveporexton, promising phase 3 gains in wakefulness and cataplexy for narcolepsy type 1.

02/09/2026

💊The interactive February digital issue of Psychiatric Times is now live! This month, our exclusively-online issue puts a spotlight on antidepressant withdrawal.

Explore the issue now and follow along as articles are shared throughout the month. https://indd.adobe.com/view/5e75daed-86f0-43ab-8dc3-eaa07d53856b

02/06/2026

Women with both depression and anxiety demonstrated an approximately 78% increased risk of developing long COVID compared with women without these conditions. Learn more in this video:

Research reveals that individuals with preexisting mental illnesses face a significantly higher risk of developing long COVID, emphasizing the need for targeted support.

02/05/2026

New data shows negative allosteric modulator targeting metabotropic glutamate receptor 7 may be transformative in treating anxiety and fear-related disorders such as PTSD.

Preclinical mGlu7 negative allosteric modulator ADX71743 disrupts fear-memory reconsolidation.

02/04/2026

According to an update from nonprofit Active Minds, there is now a push to place information about #988 on student ID cards for the very first time. Learn more about this news here:

Congress backs printing 988 on student ID cards, boosting youth crisis access and funding.